Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...

Telix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imaging MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of...

Telixが日本で腎臓がん用画像診断薬の臨床治験を開始 メルボルン, オーストラリア および京都, 日本, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals...

Telix Pharmaceuticals to Launch Japanese Renal Cancer Imaging Study MELBOURNE, Australia and KYOTO, Japan, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...

Telix Completes Acquisition of Atlab for Prostate Cancer Program MELBOURNE, Australia and NANTES, France, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced completion of the acquisition of Atlab Pharma SAS...